Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
Gralla J and Wiseman AC | Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. | 2009 | Transplantation | pmid:19502965 |
Morrissey PE | Prope tolerance: is it the end or the means? | 2009 | Transplantation | pmid:19502973 |
Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
Prókai à et al. | Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. | 2016 | Transplantation | pmid:26502369 |
Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
Muthukumar T et al. | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. | 2013 | Transplantation | pmid:23503504 |
Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
Ishizuka J et al. | Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. | 1993 | Transplantation | pmid:7506454 |
Dhar DK et al. | Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. | 1993 | Transplantation | pmid:7506456 |
Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
Abu-Qaoud MS et al. | Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. | 2012 | Transplantation | pmid:23044666 |
Woodward RS et al. | Renal graft survival and calcineurin inhibitor. | 2005 | Transplantation | pmid:16177637 |
Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
Uemura T et al. | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. | 2011 | Transplantation | pmid:21841541 |
Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
Jacobson PA et al. | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. | 2011 | Transplantation | pmid:21206424 |
Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
Mikhalski D et al. | Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. | 2008 | Transplantation | pmid:18401260 |
Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
Nakazawa Y et al. | Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. | 1998 | Transplantation | pmid:9808496 |
Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |
Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |